Risk scoring based on expression of long non-coding RNAs can effectively predict survival in hepatocellular carcinoma patients with or without fibrosis

被引:30
作者
Ye, Jiaxiang [1 ]
Wu, Siyao [1 ]
Pan, Shan [1 ]
Huang, Junqi [2 ]
Ge, Lianying [1 ]
机构
[1] Guangxi Med Univ Canc Hosp, Dept Med Oncol, 71 Hedi Rd, Nanning 530021, Guangxi, Peoples R China
[2] Guangxi Med Univ Canc Hosp, Dept Pathol, Nanning 530021, Guangxi, Peoples R China
关键词
hepatocellular carcinoma; fibrosis; risk scoring system; long non-coding RNA; survival; SOCIOECONOMIC-STATUS; LIVER FIBROSIS; UNITED-STATES; HEPATITIS-B; MANAGEMENT; OUTCOMES; PACKAGE;
D O I
10.3892/or.2020.7528
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with hepatocellular carcinoma (HCC) have different prognoses depending on whether or not they also have fibrosis. Since long non-coding RNAs (lncRNAs) affect tumor formation and progression, the present study aimed to investigate whether their expression might help predict the survival of patients with HCC. Expression profiles downloaded from The Cancer Genome Atlas database were examined to identify lncRNAs differentially expressed (DElncRNAs) between HCC patients with or without fibrosis. These DElncRNAs were then used to develop a risk scoring system to predict overall survival (OS) or recurrence-free survival (RFS). A total of 142 significant DElncRNAs were identified using data from 135 patients with fibrosis and 72 without fibrosis. For HCC patients with fibrosis, a risk scoring system to predict OS was constructed based on five lncRNAs (AL359853.1, Z93930.3, HOXA-AS3, AL772337.1 and AC012640.3), while the risk scoring system to predict RFS was based on 12 lncRNAs (PLCE1-AS1, Z93930.3, LINC02273, TRBV11-2, HHIP-AS1, AC004687.1, LINC01857, AC004585.1, AP000808.1, CU638689.4, AC090152.1 and AL357060.1). For HCC patients without fibrosis, the risk scoring system to predict OS was established based on seven lncRNAs (LINC00239, AC104971.4, AP006285.2, HOXA-AS3, AC079834.2, NRIR and LINC01929), and the system to predict RFS was based on five lncRNAs (AC021744.1, NRIR, LINC00487, AC005858.1 and AC107398.3). Areas under the receiver operating characteristic curves for all risk scoring systems exceeded 0.7. Uni- and multivariate Cox analyses showed that the risk scoring systems were significant independent predictors of OS for HCC patients with fibrosis, or of OS and RFS for HCC patients without fibrosis, after adjusting for clinical factors. Functional enrichment analysis suggested that, depending on the risk scoring system, highly associated genes were involved in pathways mainly associated with the cell cycle, chemokines, Th17 cell differentiation or thermogenesis. The findings of the present study indicate that risk scoring systems based on lncRNA expression can effectively predict the OS of HCC patients with fibrosis as well as the OS or RFS of HCC patients without fibrosis.
引用
收藏
页码:1451 / 1466
页数:16
相关论文
共 32 条
  • [1] Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods
    Abdalla, Ahmed F.
    Zalata, Khaled R.
    Ismail, Abeer F.
    Shiha, Gamal
    Attiya, Mohamed
    Abo-Alyazeed, Ahmed
    [J]. FIBROGENESIS & TISSUE REPAIR, 2009, 2
  • [2] Race, Ethnicity, and Socioeconomic Status Influence the Survival of Patients With Hepatocellular Carcinoma in the United States
    Artinyan, Avo
    Mailey, Brian
    Sanchez-Luege, Nicelio
    Khalili, Joshua
    Sun, Can-Lan
    Bhatia, Smita
    Wagman, Lawrence D.
    Nissen, Nicholas
    Colquhoun, Steven D.
    Kim, Joseph
    [J]. CANCER, 2010, 116 (05) : 1367 - 1377
  • [3] Hepatocellular carcinoma: clinical frontiers and perspectives
    Bruix, Jordi
    Gores, Gregory J.
    Mazzaferro, Vincenzo
    [J]. GUT, 2014, 63 (05) : 844 - 855
  • [4] Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: A population-based study
    El-Serag, HB
    Siegel, AB
    Davila, JA
    Shaib, YH
    Cayton-Woody, M
    McBride, R
    McGlynn, KA
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 158 - 166
  • [5] The Clinical Management of Hepatocellular Carcinoma in the United States, Europe, and Asia A Comprehensive and Evidence-Based Comparison and Review
    Fong, Zhi Ven
    Tanabe, Kenneth K.
    [J]. CANCER, 2014, 120 (18) : 2824 - 2838
  • [6] Hepatocellular carcinoma
    Forner, Alejandro
    Reig, Maria
    Bruix, Jordi
    [J]. LANCET, 2018, 391 (10127) : 1301 - 1314
  • [7] Evolving challenges in hepatic fibrosis
    Friedman, Scott L.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (08) : 425 - 436
  • [8] A three-long non-coding RNA-expression-based risk score system can better predict both overall and recurrence-free survival in patients with small hepatocellular carcinoma
    Gu, Jingxian
    Zhang, Xing
    Miao, Runchen
    Ma, Xiaohua
    Xiang, Xiaohong
    Fu, Yunong
    Liu, Chang
    Niu, Wenquan
    Qu, Kai
    [J]. AGING-US, 2018, 10 (07): : 1627 - 1639
  • [9] LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis
    Huang, Yuqi
    Xiang, Bo
    Liu, Yuanhua
    Wang, Yu
    Kan, Heping
    [J]. CANCER LETTERS, 2018, 437 : 56 - 66
  • [10] Fibrosis and AST to platelet ratio index predict post-operative prognosis for solitary small hepatitis B-related hepatocellular carcinoma
    Hung, Hung-Hsu
    Su, Chien-Wei
    Lai, Chiung-Ru
    Chau, Gar-Yang
    Chan, Che-Chang
    Huang, Yi-Hsiang
    Huo, Teh-Ia
    Lee, Pui-Ching
    Kao, Wei-Yu
    Lee, Shou-Dong
    Wu, Jaw-Ching
    [J]. HEPATOLOGY INTERNATIONAL, 2010, 4 (04) : 691 - 699